Erratum: Expression of concern: “Plasma homocysteine and polycystic ovary syndrome: The missed link” [EJOG 131(1) 2007 68–72] (European Journal of Obstetrics and Gynecology (2007) 131(1) (68–72), (S0301211506005665), (10.1016/j.ejogrb.2006.10.015));Plasma homocysteine and polycystic ovary syndrome: The missed link

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 131, Issue 1, 2007, Pages 68-72

  Badawy, Ahmed ^a   State, Omnia ^a   El Gawad, Soma Sh Abd ^a   El Aziz, Omar Abd ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Homocysteine; Insulin resistance; PCOS

Indexed keywords

HOMOCYSTEINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EGYPT; FEMALE; FEMALE INFERTILITY; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 33847102242     PISSN: 03012115     EISSN: 18727654     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2024.06.038     Document Type: Erratum

References (43)

1. Dunaif A., Segal K.R., Shelley D.R., Green G., Dobrjansky A., and licholai T. Evidence of distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41 (1992) 1257-1266
2. Gennarelli G., Holte J., Berglund L., Berne C., Massobrio M., and Lithel H. prediction models for insulin resistance in the polycystic ovary syndrome. Human Reprod 15 (2000) 2098-2102
3. Talbott E., Guzick D., Cleici A., and Berga S. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 15 (2001) 821-826
4. Dahlgren E., and Janson P. Long-term health complications in women with polycystic ovary syndrome. In: Kovacs G.T. (Ed). Polycystic ovary syndrome (2000), Cambridge University Press, Cambridge 70-79
5. Giltay E.J., Hoogeveen E.K., Elbers J.M., Gooren L.J., Asscheman H., and Stehouwer C.D. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J Clin Endocrinol Metab 83 (1998) 550-553
6. Van Baal W.M., Smolers R.G., and Van der Mooren M.J. Hormone replacement therapy and plasma homocysteine levels. Obstet. Gynecol. 94 (1999) 485-491
7. McCarthy M.F. Insulin secretion as a potential determinant of homocysteine levels. Med Hypotheses 55 (2000) 454-455
8. Nygard O., Vollset S.E., Ueland P.M., and Refsum H. Major life-style determinants of plasma homocysteine distribution. The Hordaland Homocysteine Study. Am J Clin Nutr 67 (1998) 263-270
9. Schneede J., Refsum H., and Ueland P.M. Biological and environmental determinants of plasma homocysteine. Semin Thromb Hemost 26 (2000) 263-279
10. House J.D., Jacobs R.L., Stead L.M., Brosnan M.E., and Brosnan J.T. Regulation of homocysteine metabolism. Adv Enzyme Regul 39 (1999) 69-91
11. McCarthy M.F. Increased homocysteine associated with smoking, chronic inflammation and ageing may reflect acute-phase inductions of pyroxidal phosphatase activity. Med Hypotheses 55 (2000) 289-293
12. Henning B.F., Riezler R., Tepel M., et al. Evidence of altered homocysteine metabolism in chronic renal failure. Nephron 83 (1999) 314-322
13. Sheu W.H., Lee W.J., and Chen Y.T. Plasma homocysteine concentration and insulin sensitivity in hypertensive subjects. Am J Hypertens 13 (2000) 14-20
14. Nygard O., Vollset S.E., Refsum H., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. J Am Med Assoc 274 (1995) 1526-1533
15. Das S., Reynolds T., Patnaik A., Rais N., Fink L., and Fonseca V. Plasma homocysteine in type II diabetic patients in India: relationship to body weight. J Diab Compl 13 (1999) 200-203
16. Knekt P., Alfthan G., Aromaa A., et al. Homocysteine and major coronary events: a prospective population study amongst women. J Intern Med 249 (2001) 461-465
17. McFarlane S.I., Banjeri M., and Showers J.R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86 (2001) 713-718
18. Adams J., Polson D.W., and Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 293 (1986) 355-359
19. Hanson R.L., Prately R.E., Bogardus C., et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151 (2000) 190-198
20. Mather K.J., Hunt A.E., Steinberg H.O., et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 86 (2001) 5457-5464
21. Meigs J.B., Jacques P.F., Selhub J., et al. Fasting homocysteine levels in insulin resistance syndrome. Diabetes Care 24 (2001) 1403-1410
22. Laivuori H., Kaaja R., Turpeinen U., Viinika L., and Ylikorkala O. Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia. Obstet Gynecol 93 (1999) 489-493
23. Yarali H, Yildiz A, Aybar F, et al. Left ventricular diastolic functions may be impaired in polycystic ovarian syndrome. Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE), June 2000. Bologna, Italy, Abstract 0-180, p. 72-3.
24. Yarali H., Yildiz A., Aybar F., et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovarian syndrome. Fertil Steril 76 (2001) 511-516
25. Bayraktar F., Dereli D., Ozgen G., and Yilmaz C. Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. Endocr J 51 6 (2004) 601-608
26. Sills E.S., Genton M.G., Perloe M., and Schattman G.L. Plasma homocysteine, fasting insulin, and androgen patterns among women with polycystic ovaries and infertility. J Obstet Gynecol Res 27 (2001) 163-168
27. Kilic-Okman T., Guldiken S., and Kucuk M. Relationship between homocysteine and insulin resistance in women with polycystic ovary syndrome. Endocr J 51 5 (2004) 505-508
28. Rosolova H., Simon J., Mayer O., Racek J., Dierze T., and Jackobson D.W. Unexpected inverse relationship between insulin resistance and serum homocysteine in healthy subjects. Physiol Res 51 (2002) 93-98
29. Vrbikova J., Bicikova M., Tallova J., Hill M., and Straka L. Homocysteine and steroid levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diab 110 (2002) 74-76
30. Tasanedis G., Vartholomatos G., Korkontzelos I., et al. Polycystic ovarian syndrome and thrombophilia. Hum Reprod 17 (2002) 314-317
31. Nelen W.L.D.M., Blom H.J., Steegers E.A.P., Den Heijer M., and Eskes T.A.K.B. Hyperhomocysteinemia and recurrent early pregnancy loss: a metaanalysis. Fertil Steril 74 (2000) 1196-1199
32. Quere I., Mercier E., Bellet H., Janbon C., Mares P., and Gris J.C. Vitamin supplementation and pregnancy outcome in women with recurrent pregnancy loss and homocysteinemia. Fertil Steril 75 (2001) 823-825
33. Stamler J.S., Osborne J.A., Jaraki O., Rabbani L.E., and Single D. Adverse vascular effects of homocysteine are modulated by endothelium derived relaxing factors and related oxides of nitrogen. J Clin Invest 91 (1998) 308-318
34. Coppola A., Davi G., De Stefano V., Mancini F., Cerbone A., and DiMinno G. Homocysteine, coagulation, platelet function and thrombosis. Semin Thromb Hemost 26 (2000) 243-254
35. Mujumdar V.S., Tummallaplli C.M., Aru G.M., and Tyagi S.C. Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR. Am J Physiol Cell Physiol 282 (2002) 1009-1015
36. Van Guldener C., and Stehouwer C.D. Hyperhomocysteinemia, vascular pathology and endothelial dysfunction. Semin Thromb Hemost 26 (2000) 281-289
37. Zhang C., Yong C., Adachi M.T., et al. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of unfolded protein response. J Biol Chem 276 (2001) 35867-35874
38. Goldstein BJ, Haffner SM, Hseuh WA. Insulin resistance implications for metabolic and cardiovascular diseases. CME Circle Diabetes and Endocrinology continuing medical education online: www.medscape.com/CME Circle/Diabetes/2001.
39. Audelin M.C., and Genest J. Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 159 (2001) 497-511
40. Atiomo W., Bates S., Condon J., Shaw S., West J., and Prentice A. The plasminogen activator inhibitor system in women with polycystic ovary syndrome. Fertil Steril 69 (1998) 236-241
41. Paradisi G., Steinberg H.O., Hempfling A., Cronin J., Hook J., and Baron A.D. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 103 (2001) 1410-1415
42. Diamanti-Kandarkis E., Spina G., Kouli C., and Migdalis I. Increased endothelin I levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 86 (2001) 4666-4673
43. Sabuncu T., Vural H., Harma M., and Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 34 (2001) 407-413